About cardiovascular risk assessment in the new clinical trials with statins [6];¿Dónde queda el cálculo del riesgo cardiovascular en los nuevos ensayos clínicos con estatinas?

Medicina Clinica

Volumn 122, Issue 14, 2004, Pages 559-

  Martín Luján, Francisco ^a   Baldrich Justel, Marta ^a   Solà Alberich, Rosa ^b   Basora Gallisà, Josep ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PRAVASTATIN; STATINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MALE; PREVALENCE; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HYPERCHOLESTEROLEMIA; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RISK ASSESSMENT; RISK FACTORS;

EID: 3343012319     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13060480     Document Type: Letter

References (10)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
2. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
3. Sever PS, Dahlöf B, Pouler NR, Wedel H, Beevers G, Caulfield M, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower thab average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (AS-COT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58.
4. Robson J, Feder G. Predicting and reducing cardiovascular risk. Heart 2001;85:487-8.
5. Executive summary of the Third Report of the National Cholesterol Education Program (NECP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Brotons C, Cascant P, Ribera A, Moral I, Permanyer G. Utilidad de la medición del riesgo coronario a partir de la ecuación del estudio de Framingham: estudio de casos y controles. Med Clin (Barc) 2003;121:327-30.
7. Gómez-Belda A, Rodilla E, Albert A, García L, González C, Pascual JM. Uso clínico de las estatinas y objetivos terapéuticos en relación con el riesgo cardiovascular. Med Clin (Barc) 2003;121:527-31.
8. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary events rates across the WHO MONICA Project populations. Lancet 2000;355:675-87.
9. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
10. Ramos R, Solanas P, Cordón F, Rohlfs I, Elosua R, Sala J, et al. Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc) 2003;121:521-6.